Home | IWG WG

IWG WG

10 / 18 results found

Antibody-mediated podocytopathies: a disease entity that implies immunotherapy

July 17, 2024

IWG WG

Immunoengineering for autoimmune-kidney disease

June 21, 2024

IWG WG

IgA nephropathy and novel treatments

Speaker
Jonathan Barrat, United Kingdom

Panellists
Gema Maria Fernandez Suarez, Spain
Claudia Seikrit, Germany

Moderator
Annette Bruchfeld, Sweden

IWG WG

Management of adult patients with podocytopathies: an update from the ERA Immunonephrology Working Group

February 10, 2024

IWG WG

Lupus nephritis and new drugs

Speaker
Eleni Frangou, Cyprus

Panellist
Hans-Joachim Anders, Germany
Andreas Kronbichler, Austria

Moderator
Kate Stevens, United Kingdom

IWG WG

EULAR 2023 recommendations for SLE treatment: synopsis for the management of lupus nephritis – the European Renal Association (ERA) – Immunonephrology Working Group (ERA-IWG) perspective

October 25, 2023

IWG WG

Precision medicine and hierarchy of diagnostics and treatment in haematuria/proteinuria

Speakers
Elion Hoxha, Germany
Bertrand Knebelmann, France

Panellists
Peter Boor, Germany
Daniel Gale, United Kingdom

Moderators
Annette Bruchfeld, Sweden
Jan Halbritter, Germany

Sodium-glucose cotransporter 2 inhibition in primary and secondary glomerulonephritis

August 07, 2023

IWG WG

Management of anti-neutrophil cytoplasmic antibody associated vasculitis with glomerulonephritis as proposed by the ACR 2021, EULAR 2022 and KDIGO 2021 Guidelines/Recommendations

May 11, 2023

IWG WG

Prophylactic and early outpatient treatment of COVID-19 in patients with kidney disease: considerations from the Immunonephrology Working Group of the European Renal Association (ERA-IWG)

March 07, 2023

IWG WG

Webcast available!

Webcast available!

Suggestions

IWG WG

{%TITLE%}

{%TITLE%}

Antibody-mediated podocytopathies: a disease entity that implies immunotherapy

Immunoengineering for autoimmune-kidney disease

IgA nephropathy and novel treatments

Management of adult patients with podocytopathies: an update from the ERA Immunonephrology Working Group

Lupus nephritis and new drugs

EULAR 2023 recommendations for SLE treatment: synopsis for the management of lupus nephritis – the European Renal Association (ERA) – Immunonephrology Working Group (ERA-IWG) perspective

Precision medicine and hierarchy of diagnostics and treatment in haematuria/proteinuria

Sodium-glucose cotransporter 2 inhibition in primary and secondary glomerulonephritis

Management of anti-neutrophil cytoplasmic antibody associated vasculitis with glomerulonephritis as proposed by the ACR 2021, EULAR 2022 and KDIGO 2021 Guidelines/Recommendations

Prophylactic and early outpatient treatment of COVID-19 in patients with kidney disease: considerations from the Immunonephrology Working Group of the European Renal Association (ERA-IWG)